Context-Insulin resistance is not fully explained on a molecular level, though several genes and proteins have been tied to this defect. Knockdowns of the SEPP1 gene, which encodes the Selenoprotein P (SeP) protein, have been shown to increase insulin sensitivity in mice. SeP is a liver-derived plasma protein and a major supplier of selenium, which is a proposed insulin mimetic and antidiabetic agent.
Introduction
Selenoproteins are the primary sequestering unit of selenium obtained from the diet. Most selenoproteins contain only one selenocysteine residue at the enzyme active site, though selenoprotein P (SeP) in humans and rodents harbors 10 of these (Hill et al., 1993) . Selenium is a nutrient essential for human health, and has been shown to play a role in proper immune function, thyroid function, and fertility (Schwarz and Foltz, 1958; Hill et al., 2003; Beckett and Arthur, 2005; Ferguson et al., 2012) . Serum selenium levels have been shown to correlate with serum lipids in several studies (Stranges et al., 2010; Stranges et al., 2011) . Selenium is also an insulin mimetic and has anti-diabetic properties in mouse models (Stapleton, 2000) . Selenoprotein P, encoded by the SEPP1 gene, is present in the plasma at high concentrations (5-6 mg/liter) in humans (Burk et al., 2001) . Two isoforms of this protein in humans have been well documented; one containing the full length transcript and all 10 selenocysteine residues, and the other is truncated prematurely, leaving only 1 selenocysteine residue (Mostert et al., 1998) . Newer evidence suggests that there might be three isoforms, however, one of these did not contain any selenocysteine residues (Ballihaut et al., 2012) . The liver produces most plasma SeP, contributing about 75% to the circulation, though almost all tissues express the protein, (Dreher et al., 1997) . Serum levels of SeP in humans are considered a biomarker of selenium status in the entire body (Xia et al., 2005) . SeP has been widely studied for association with metabolic health, including measures of insulin sensitivity, glucose control, body mass, C-reactive protein, serum lipids and carotid intimamedia thickness (Yang et al., 2011) . SeP levels and/or expression have been associated with insulin resistance (Misu et al., 2010; Zeng et al., 2012) , obesity (Zhang and Chen, 2010; Choi et al., 2013) and nonalcoholic fatty liver disease in humans and animal models.
Genetic variation in SEPP1 has been reported to be associated with several metabolic phenotypes. Two single nucleotide polymorphisms (SNPs) in SEPP1 were reported to have functional consequences on protein level and\or function. The coding SNP rs3877899 (Ala234Thr) has been shown to influence plasma selenium levels as well as plasma levels of SeP in both European Americans and South Asians (Meplan et al., 2007; . A SNP in the 3′ UTR (rs7579) has also been shown to affect the response of SeP to supplementation of selenium in the same populations (Meplan et al., 2007) . Both of these variants also influenced the proportion of two SeP isoforms (~60 and ~50 kDa) in men and women taking selenium (Se) supplements (Meplan et al., 2007) . Genetic variants within SEPP1 have not previously been evaluated for association with measures of insulin resistance, insulin response, or adiposity.
The roles of selenium and SeP with the pathophysiology of type 2 diabetes (T2D) have been recently reviewed, with conclusions that although there is significant evidence linking selenium and SeP to glucose metabolism and insulin resistance, the relationship between SeP and selenium, and T2D is complex and necessitates further study (Mao and Teng, 2013; Rayman and Stranges, 2013) . The hypothesis for this study was that coding and non-coding variants in SEPP1 would be associated with dynamic measures of glucose homeostasis and adiposity as well as related traits, such as inflammation, liver density and lipid levels.
Methods

Samples
The primary sample used for this study was the Hispanic cohort of the Insulin Resistance and Atherosclerosis Family Study (IRASFS) (Henkin et al., 2003) . Briefly, subjects were ascertained on the basis of large family size in San Luis Valley, Colorado and San Antonio, Texas. Recruitment was based on family size rather than specific clinical characteristics. Sample phenotypes are summarized in Table 1 . These subjects were extensively phenotyped, including a frequently sampled intravenous glucose test (FSIGT), measures of blood lipids and inflammatory markers, anthropomorphic measures, as well as fat deposition and liver density measures by computed tomography (CT) scan. Insulin sensitivity (S I ) was calculated from FSIGT data using mathematical modeling methods (MINMOD version 3.0; Harms Software, Los Angeles, CA). Acute insulin response (AIR) was calculated as the mean of 2-and 4-min insulin concentrations after glucose administration. Metabolic clearance rate of insulin (MCRI) was calculated as the ratio of the insulin dose over the incremental area under the curve of insulin from 20 min to infinity.
A second sample group was from the Insulin Resistance Atherosclerosis Study (IRAS), a predecessor of IRASFS. IRAS is a multi-ethnic epidemiological cohort of unrelated subjects consisting of 480 European Americans, 384 Hispanics and 288 African Americans (Wagenknecht et al., 1995) . These samples were phenotyped in a manner similar to the IRASFS with FSIGT measures, blood lipids and a limited number of inflammatory markers. IRB approval was obtained at all clinical and analysis sites and all participants provided informed consent.
SNP Selection and Genotyping
SNPs were chosen to tag the SEPP1 gene using HaploView (r 2 = 0.8) in the HapMap CEU (CEPH: Utah residents with ancestry from northern and western Europe) and MEX (Mexican ancestry in Los Angeles, California) populations, including SNPs from the promoter region. Additional coding SNPs from the NHLBI Exome Sequencing Project database (http://snp.gs.washington.edu/EVS) were also included for genotyping ( Table 2) . Genotyping of SNPs was performed using the Sequenom iPlex Mass Array system (Sequenom; San Diego, CA) (Gabriel et al., 2009) . Blind duplicates (n=80) were genotyped for quality control purposes and had a concordance rate of greater than 98.5%. SNP and plate call rate thresholds were set at >90%. Only one SNP (rs28919923) failed to exceed this threshold in the initial IRASFS genotyping; none failed in the multi-ethnic IRAS cohort.
Statistical Analysis
PedCheck (O'Connell and Weeks, 1998) was used to identify Mendelian inconsistencies in the data (N=72) and they were resolved by removing conflicted genotypes (n=118). Hardy-Weinberg equilibrium and linkage disequilibrium were assessed using a subset of unrelated individuals (n=229) and the Haploview program (Barrett et al., 2005) . Hardy-Weinberg pvalues ranged from 0.0045-1, with only 1 variant (rs6897301) having a p-value less than 0.01. Association analysis for IRAS-FS was performed using Sequential Oligogenic Linkage Analysis Routines (SOLAR) (Almasy and Blangero, 1998) . The effective number of SNPs was computed using the Moskvina & Schmidt method in SOLAR as 16 independent SNPs based on LD correlations, and the required p-value for significance after correction was set at 0.0032. Although several phenotypes were analyzed with these SNPs, many of these are correlated with one another, for instance, BMI and S I , and therefore they were not accounted for in the number of comparisons. Hardy-Weinberg equilibrium and association analysis for the IRAS samples were performed separately for each ethnic group using PLINK v1.07 (Purcell et al., 2007) . One SNP (rs16872779) deviated from Hardy-Weinberg equilibrium in the IRAS HA sample (p=4.27 × 10 −8 ) and was subsequently removed from analysis for this sample set. Trait variables were transformed to approximate normal distributions as follows: S I , fasting insulin, HOMA-IR, MCRI, total cholesterol, HDL, BMI, VSR, waist circumference, WHR, fibrinogen, and PAI-1 were log transformed, ApoB, LDL, SAT and VAT were square root transformed, and DI and AIR were square root transformed but retained the mathematical sign of the original value. Fasting glucose and glucose effectiveness were not transformed. Covariates used in the analysis included age, sex, BMI, recruitment center, and admixture estimates (admixture estimates were used in IRASFS only; IRAS samples were analyzed within ethnic group). Admixture was estimated using a principal component analysis of 80 ancestry informative markers (AIMs) (Palmer et al., 2010) . BMI was omitted as a covariate when assessing BMI, but was used for all other measures of adiposity and body composition. Meta-analysis was performed using the fixed effects model implemented in METAL (Willer et al., 2010) .
Results
The initial analysis included 1424 Hispanic individuals from 90 families in the IRASFS. Demographic characteristics of these IRASFS subjects and, in addition, subjects from IRAS, are summarized in Table 1 . The sample is representative of a cross section of the Hispanic population with both rural (San Luis Valley, CO) and urban (San Antonio, TX) areas represented. Twenty-one SNPs (Table 2, Figure 1 ) chosen to tag the SEPP1 gene and to test known coding variants in the population were successfully genotyped in this Hispanic sample. The results of association analysis of the resulting data are shown in Table 3 which lists all nominal (p < 0.01) associations found with SEPP1 SNPs and all available phenotypes. A complete listing of association analysis results is summarized in Supplementary Table 1. Two coding SNPs showed evidence of association with acute insulin response (AIR): rs28919926 (Cys368Arg) and rs146125471 (Ile293Met) with pvalues of 0.0028 and 0.0026, respectively. These two SNPs were perfectly correlated (r 2 =1) in this sample (Supplemental Figure 1 ). These two SNPs were also strongly associated with insulin clearance (MCRI; p=0.0016 and 0.0010). A different SNP (rs16872779) was nominally associated with fasting insulin levels (p=0.0097). Nominal associations were also seen with homeostatic model assessment of insulin resistance (HOMA-IR) (7 SNPs p<0.05, 6 additive model, 1 recessive) and S I (3 SNPs p<0.05, 2 additive, 1 dominant). The cytokine IL6, a marker of inflammation, was also significant with two SNPs (rs72554691 and rs7719242; p=0.00052, additive, and 0.0083, dominant respectively), and nominally associated with an additional two SNPs (p<0.05, 1 dominant, 1 recessive) while TNFreceptor 1 levels were significantly associated with two non-coding SNPs (rs12519443; p=0.0040 and rs7719242, p=0.0048, both recessive model). Measures of adiposity were also associated with SNPs in this gene: two SNPs, rs16872762 and rs28919891 were associated with visceral adipose tissue (VAT; p=0.0086, additive, and 0.00016, recessive, respectively), one of which (rs16872762) was also associated with waist/hip ratio (WHR; p=0.0091, additive). The SNP rs16872762 was also nominally associated (p<0.05) with both visceral to subcutaneous ratio and waist circumference. One variant was also associated with apolipoprotein B (ApoB) levels under a dominant model: rs6413428 with a p-value of 0.0028.
To further analyze these SNPs in a variety of ethnic groups, the multi-ethnic IRAS sample was genotyped and association analysis performed. All 21 SNPs were successfully genotyped in this sample. Each of the three ethnic groups was analyzed separately for association. In the IRAS Hispanics (n=384; Supplemental Table 2a ), notable associations included rs230819 with fibrinogen (p=0.0061, recessive), rs4987017 with ApoB (p=0.0017, dominant), rs6882786 with plasminogen activator inhibitor-1 (PAI-1; p=0.0096, additive), and rs7579 with fasting insulin and LDL (p=0.0078, additive, and 0.0044, dominant, respectively). The latter replicates the observation that increased LDL levels were nominally associated with rs7579 in the IRASFS cohort (p=0.026, dominant). None of the other variants replicated the direction of effect of associated traits from IRASFS. Several associations were found with alternative traits in the European Americans (Supplemental Table 2b ) and African Americans (Supplemental Table 2c ) in IRAS. Many of these results, e.g. rs6413428, rs10512806, and rs3877899 with ApoB (p<0.01), support evidence of association seen in the IRASFS Hispanic sample.
Meta-analysis of the three ethnic groups in IRAS (Table 4 ) revealed several SNPs with evidence of association with glucose homeostasis traits (p<0.05). The SNP rs6882786 was associated with S I , AIR and fasting insulin with p-values <0.05. Nominal associations were seen with rs7579 and S I , rs13154178 and fasting glucose, and rs1672762 and AIR.
Combining results from the larger IRASFS Hispanic cohort (n=1424) with the smaller IRAS Hispanic cohort (n=384) using meta-analysis revealed suggestive evidence for association with glucose homoeostasis traits (Supplementary Table 3 ). Both rs146125471 and rs28919896 were associated with AIR (p=0.0041 and 0.0047, respectively), while four SNPs were associated with fasting insulin levels (rs230819, rs16872779, rs16872762, and rs7579; p<0.02). One of these, rs230819, was also associated with S I (p=0.011). Additionally, ApoB levels were associated with two SNPs (rs6413428 and rs4987017) which were also associated with BMI and total cholesterol levels, respectively. Another SNP, rs3877899 was also associated with BMI.
Meta-analysis of all cohorts (Table 5 ) identified several variants with consistent direction of effect across all ethnic groups. For the glucose homeostasis traits, the most significant result was rs146125471 with AIR (meta-analysis p-value of 0.0047, additive model). Additionally, rs16872762 was associated with fasting insulin with a p-value of 0.028 (additive), while rs7579 was associated with S I (p=0.047, dominant) and rs28919926 was associated with AIR (p=0.013, additive). Inflammatory markers were also associated across cohorts, with four markers being associated with fibrinogen (rs6882786, p=0.0042, dominant; rs77199242, p= 0.0056, dominant; rs7579, p= 0.0191, additive; and rs230819, p=0.0263, dominant), as well as rs12519943 with plasminogen activator inhibitor-1 (PAI-1, p=0.027, dominant). One of the lipid trait associations seen in the Hispanic meta-analysis remained associated in the full meta-analysis (rs4987017 with ApoB, p=0.031, dominant), and another SNP (rs1052806, p=0.039, recessive) also was associated with this trait. Additionally, rs6882786 was associated with total cholesterol (p=0.020, dominant).
Discussion
While individual SEPP1 SNPs do not yield striking evidence of association, overall there was a consistent pattern for association of SEPP1 variants with multiple metabolic measures. This was consistent with the functional role ascribed to the SeP protein, that is, regulation of metabolic processes. Many of these glucometabolic traits are correlated so a specific target for SEPP1 is unclear, but these results are consistent with a global influence on metabolism. The prior literature suggested a role for SeP in insulin resistance and we hypothesized that we would see some evidence of association with measures of glucose homeostasis. Several such measures were in fact associated with polymorphisms in this gene (e.g. rs146125471 with AIR). The associations seen with ApoB suggest a further link to metabolic syndrome as well. Consistent with this is the striking associations with seen with fibrinogen, a thrombotic factor which has been shown to associate with increased risk of cardiovascular disease in diabetes patients (Ganda and Arkin, 1992; Bruno et al., 2001 ).
Previous studies of variants in SEPP1 have focused on plasma selenium levels and response to selenium supplementation (Meplan et al., 2007; Penney et al., 2012) . Other studies have examined the link between SEPP1 variants and SeP isoform concentrations (Meplan et al., 2009) . Two variants (rs230813 and rs230819) in SEPP1 were shown to be nominally associated (p=0.03 and 0.02) with plasma malondialdehyde, a marker of oxidative stress, but not with measures of SeP or other selenoprotein activities (Takata et al., 2012) . Another SEPP1 variant (rs3877899) was shown to be correlated with thioredoxin reductase activity (p<0.003, major allele homozygote and heterozygote genotypes), as well as with glutathione peroxidase 1 (GPX1) activity, but not with DNA damage after peroxide challenge . Additionally, the SEPP1 SNP rs7579 was nominally associated (p<0.05) with reduced urine and hair mercury levels in a study of dental professionals (Goodrich et al., 2011) . Other variants from a variety of glutathione s-transferases and glutathione synthesizing enzymes were also associated with one or both of those biomarkers.
Studies of genetic variation in other selenoproteins are often focused on the relationship of these genes and variants to colorectal cancer risk (Meplan et al., 2009; Méplan and Hesketh, 2012; Slattery et al., 2012) . Variants in genes encoding glutathione peroxidases 1-4 were examined for association with markers of oxidative stress (plasma malondialdehyde and protein carbonyl content), GPX1 activity, GPX3 activity and SeP concentration (Takata et al., 2012) . Only two SNPs in GPX2 (rs4902346 and rs2071566) were shown to associate with SeP concentration; none of the other tests were significant. SeP expression has been observed in macrophages which are suggested to have a role in protection against development of atherosclerosis (Brocheriou et al., 2011) . Additionally, human SeP levels were found to be predictive of serum adiponectin levels (Misu et al., 2012) , which are negatively correlated with type 2 diabetes and cardiovascular disease, though no SNP was associated with adiponectin at P<0.05 (Supplemental Table 1 ) in the present study. Additional studies have shown that adiponectin treatment protected from insulin resistance when induced with palmitate cells via the inhibition of SeP (Jung et al., 2013) .
It has previously been shown that treatment of mice with purified human SeP resulted in glucose intolerance and insulin resistance (Misu et al., 2010) . That group also demonstrated that knockdown of SeP using siRNA techniques improved both glucose tolerance and insulin resistance. In the same study, mice which were SeP-deficient showed reduced plasma insulin after feeding, while blood glucose levels remained the same. These knockout mice did show improved glucose tolerance, as well as an improved response of glucose to insulin injection. High fat, high sucrose diet in these mice did not result in significantly different weight gain between wild-type and knockout groups. This work extended the findings from a previous study in which SeP knockout mice had severely impacted motor control, loss of weight, and abnormal selenium distribution when presented with low selenium intake, but glucose homeostasis was not measured in this set of experiments either (Hill et al., 2003) .
Another study did examine the effect on selenium on glucose and body weight in streptozotozin-induced diabetic and non-diabetic rats, finding that selenite treatment resulted in a decrease in blood glucose in diabetic rats, but a slight increase in blood glucose in their non-diabetic counterparts (Can et al., 2005) . Treatment also impacted liver tissue morphology, reversing the ultrastructural alterations seen in the untreated diabetic animals with little side effect. Comparison of several selenoprotein enzyme activity levels revealed that diabetic rats not treated with selenite had significantly lower activities than untreated control rats at 5 out of 6 selenoproteins measured (p<0.05, glutathione reductase, glutathione peroxidase, glutathione-6-phosphate dehydrogenase, glutathione-S-transferase and 6-phosphogluconate dehydrogenase, but not acid soluable sulphydryls), while treated diabetic rats had higher glutathione reductase activity and lower glutathione-6-phosphate dehydrogenase activity compared to their untreated counterparts, and higher acid soluable sulphydryls activity when compared to the control animals. This study, however did not examine SeP activity.
This work is the first comprehensive analysis of SEPP1 variants and glucometabolic traits. A limitation of the study is that we did not have selenium concentrations or selenoprotein enzyme activity levels available for these subjects. That data would be extremely valuable to elucidate the molecular and biochemical mechanisms connecting SEPP1 genetic variants with the variety of glucometabolic traits, given the association data generated by this work. Despite this limitation, these genetic results are consistent with the literature suggesting an important role for SEPP1 in metabolic disease.
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Highlights
• Literature suggests link between selenium and insulin resistance mediated by SEPP1
• Evaluation of 22 polymorphisms in SEPP1 region with measures of glucose homeostasis
• Several SEPP1 SNPs show evidence of association with various metabolic measures
• Many of these traits are correlated, so a specific target for SEPP1 remains unclear
• Some associations were found to be of consistent direction across ethnic groups Genotyped SEPP1 SNPs with respect to the coding region. Black diamonds represent SNP location and items in bold are coding variants. Table 2 SEPP1 SNPs genotyped with position, function, and minor allele frequencies by cohort. Table 3 Selected (P<0.01) association results of SEPP1 SNPs in the IRASFS samples. P-values less than 0.05 are indicated in boldface. NA indicates that the model was unable to be calculated due to a lack of rare homozygotes for that SNP.
1 Standard error.
Table 4
Meta Analysis of IRAS cohorts 
